health
2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Moody? Aggressive? You could have ‘irritable male syndrome’
New York Post

Ozempic and Wegovy linked to brain health risks from caloric cuts
Fox News

After 20 Miscarriages, Mom Celebrates Son’s First Birthday: ‘I Couldn’t Give Up’ (Exclusive)
Yahoo

5 Georgia siblings diagnosed with measles
WSB-TV

People Who Drink Their Own Pee Are Obsessed With AI, Using It to Reassure Themselves That It's a Miraculous Cure-All
Futurism